Business · 02/12/2003Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ELOXATIN Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for ELOXATIN, a human drug product, in response to a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →